Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03891914
Other study ID # CHUBX 2017/32
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date November 12, 2019
Est. completion date November 12, 2022

Study information

Verified date March 2022
Source University Hospital, Bordeaux
Contact Charles MESGUICH, Dr
Phone 05 56 77 47 18
Email charles.mesguich@chu-bordeaux.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multiple myeloma (MM) survival has been improved during the last decade owing to new treatments. Hence, it has become a matter of importance to precisely define the depth of MM response to therapy. 18F-FDG PET/CT (FDG-PET) has proved to be superior to X-rays for the initial staging of MM. It is now recommended by the International Myeloma Working Group (IMWG) during the initial work-up and for response evaluation, as it is superior to MRI in that setting. However, sensitivity of FDG-PET remains inferior to that of MRI for the initial staging of MM. Indeed, FDG-PET remains limited for the evaluation of skull lesions (due to brain physiological background) or spine infiltrative disease. Therefore, there is a need for a new diagnostic tool which could have equivalent sensitivity to that of MRI at diagnosis, and could bring better baseline information than FDG PET for therapy evaluation. Ultimately, this tool would be a one-stop-shop exam for diagnosis and patient follow-up during treatment. 18F-Choline, a tracer of phospholipids of cell membrane, has shown potential as compared to 18F-FDG in a recent retrospective study, with about 70% more lesions detected in MM patients with suspected relapsing disease. Following that perspective, our main objective is to compare prospectively, in a cohort of newly diagnosed MM, the detection rate of MM lesions by 18F-Choline PET/CT (FCH-PET) vs. FDG-PET. Our secondary objectives will be to compare the performance of both PET modalities as regard to MRI as well as the detection rate of extra-medullary lesions. Patients with MM will proceed to FCH-PET, FDG-PET and then Whole-Body MRI within 3 weeks.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date November 12, 2022
Est. primary completion date November 12, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Symptomatic Multiple Myeloma on first-line treatment as defined by 2014 International Myeloma Working Group criteria - Measurable disease either by serum or urinary monoclonal protein level or by serum free light chains assay - Age > 18 years old at time of signed consent - Beneficiary of social security insurance - Signed informed consent Exclusion Criteria: - Previous Multiple Myeloma treatment - Previous cancer with less than 5 year of complete remission (including plasmacytoma) - Chemotherapy in the 6 months preceding the inclusion - Uncontrolled diabetes mellitus - Medullary growth factor injection less than 48 hours before imaging procedures - Ongoing corticosteroid therapy, or given less than 72 hours before PET-CT imaging - Pregnant or nursing (lactating) women - Childbearing potential woman without adequate barrier contraception method (HAS criteria) - Freedom deprivated patient by judiciary or administrative decision - Patient under legal protection or unable to express its own consent - PET contraindication (known allergy to 18F-FCH or 18F-FDG or excipient) - MRI contraindication

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Positron Emission Tomography using 18F-FCH
Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FCH(or fluorocholine) for the detection of bone lesions
Positron Emission Tomography using 18F-FDG
Positron Emission Tomography imaging coupled with scanner (PET-CT). with the injection of a radiopharmaceutical drug, the 18F-FDG (or fluorodeoxyglucose) for the detection of bone lesions

Locations

Country Name City State
France Bordeaux University Hospital - Haut-Lévêque Pessac

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Bordeaux

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of whole-body bone lesions The numbers of bone lesions detected by 18F-FCH PET-CT and that are suspected to be related to multiple myeloma, will be counted. Every bone lesion will be validated by the reference test which is composed of MRI standard sequences plus whole-body diffusion MRI. A bone lesion that is not present on MRI but is present on any of the PET modalities must be validated by an expert multidisciplinary consensus. Day 0
Primary Number of whole-body bone lesions The numbers of bone lesions detected by 18F-FDG PET-CT, and that are suspected to be related to multiple myeloma, will be counted. Every bone lesion will be validated by the reference test which is composed of MRI standard sequences plus whole-body diffusion MRI. A bone lesion that is not present on MRI but is present on any of the PET modalities must be validated by an expert multidisciplinary consensus. Day 7
Primary Number of bone lesions within defined skeletal areas Six skeletal areas are defined : skull - spine - pelvis - sternum and ribs - superior limbs - inferior limbs. The number of bone lesions that are suspected to be related to myeloma in each of these skeletal area is assessed on 18F-FCH PET-CT Every bone lesion will be validated by the reference test which is composed of MRI standard sequences plus whole-body diffusion MRI. A bone lesion that is not present on MRI but is present on any of the PET modalities must be validated by an expert multidisciplinary consensus Day 0
Primary Number of bone lesions within defined skeletal areas Six skeletal areas are defined : skull - spine - pelvis - sternum and ribs - superior limbs - inferior limbs. The number of bone lesions that are suspected to be related to myeloma in each of these skeletal area is assessed on 18F-FDG PET-CT. Every bone lesion will be validated by the reference test which is composed of MRI standard sequences plus whole-body diffusion MRI. A bone lesion that is not present on MRI but is present on any of the PET modalities must be validated by an expert multidisciplinary consensus Day 7
Secondary Diagnostic performance for the detection of focal bone lesions Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FCH PET-CT will be calculated based on two different reference test. First reference test will be standard MRI sequences (T1SE, T2-STIR). Second reference test will be composed of standard MRI sequences plus whole-body diffusion MRI acquisitions. Day 0
Secondary Diagnostic performance for the detection of focal bone lesions Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET-CT will be calculated based on two different reference test. First reference test will be standard MRI sequences (T1SE, T2-STIR). Second reference test will be composed of standard MRI sequences plus whole-body diffusion MRI acquisitions. Day 7
Secondary Diagnostic performances for the detection of diffuse infiltrative disease of the spine Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FDG PET-CT will be calculated based on standard MRI sagittal acquisitions of the spine. Day 7
Secondary Diagnostic performances for the detection of diffuse infiltrative disease of the spine Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 18F-FCH PET-CT will be calculated based on standard MRI sagittal acquisitions of the spine. Day 0
Secondary Number of extra-medullary lesions Each extra-medullary lesion detected on 18F-FDG PET-CT will be validated by an expert multidisciplinary consensus Day 7
Secondary Number of extra-medullary lesions Each extra-medullary lesion detected on 18F-FCH PET-CT will be validated by an expert multidisciplinary consensus Day 0
See also
  Status Clinical Trial Phase
Active, not recruiting NCT06205823 - Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM
Recruiting NCT04782687 - Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma Phase 2
Active, not recruiting NCT05889221 - Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma N/A
Not yet recruiting NCT05944783 - Bioequivalence Studies of Dasatinib 100 mg Phase 4
Recruiting NCT04268199 - A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment Phase 2
Not yet recruiting NCT06133426 - Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients N/A
Completed NCT05887206 - Corneal Toxicity in Patients Treated by Belantamab Mafodotin
Completed NCT04065789 - Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients Phase 2
Active, not recruiting NCT03089411 - Collection of Additional Data Followed the Study IFM 2013-04 N/A
Completed NCT04436029 - Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy Phase 2
Not yet recruiting NCT04364724 - CTFEA Myeloma Study
Recruiting NCT05932680 - Limited-duration Teclistamab Phase 2
Not yet recruiting NCT06418750 - Evaluation of a Range of Dermo-cosmetic Products to Treat Skin and Nail Toxicity Linked to Bispecific Anti-GPRC5D Bispecific Antibodies in Multiple Myeloma Patients". Myeloma". Descriptive Pilot Study N/A
Completed NCT04236063 - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Terminated NCT04242121 - The Risk Stratification in Patients With Multiple Myeloma Based on Fluorescence Flow Cytometry Quantitative Determination of the Circulating Plasma Cells in the Peripheral Blood
Not yet recruiting NCT03607643 - A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies Phase 1/Phase 2
Recruiting NCT05651932 - A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma Phase 1
Not yet recruiting NCT06245629 - Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Recruiting NCT03992170 - Study of Daratumumab in Multiple Myeloma (MM) Patients in >VGPR/MRD-positive Phase 2
Terminated NCT04843579 - Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients Phase 2